Literature DB >> 9445050

An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope.

T M Fu1, L M Mylin, T D Schell, I Bacik, G Russ, J W Yewdell, J R Bennink, S S Tevethia.   

Abstract

An immunological hierarchy among three H-2Db-restricted cytotoxic T lymphocyte (CTL) determinants in simian virus 40 (SV40) large T antigen (Tag) was described previously: determinants I and II/III are immunodominant, whereas determinant V is immunorecessive. To assess the immunogenicity of each determinant individually and define mechanisms that contribute to the immunorecessive nature of determinant V, we constructed a panel of recombinant vaccinia viruses (rVVs) expressing minigenes encoding these determinants in various polypeptide contexts. We found the following. (i) Immunization of mice with an rVV encoding full-length SV40 Tag resulted in priming for CTL responses to determinants I and II/III but not determinant V. (ii) rVVs encoding peptide I or II/III in the cytosol or targeted to the endoplasmic reticulum (ER) were highly antigenic and immunogenic. (iii) rVVs encoding peptide V minigenes were antigenic and immunogenic if the peptide was targeted to the ER, expressed in the cytosol with short flanking sequences, or expressed from within a self-protein, murine dihydrofolate reductase. (iv) Presentation of the nonflanked peptide V (preceded by a Met codon only) could be enhanced by using a potent inhibitor of the proteasome. (v) H-2Db-epitope V peptide complexes decayed more rapidly than complexes containing epitope I or II/III peptides. In brefeldin A blocking experiments, functional epitope V complexes were detected longer on targets expressing ER-targeted epitope V than on targets expressing forms of epitope V dependent on the transporter associated with antigen processing. Therefore, limited formation of relatively unstable cell surface H-2Db complexes most likely contributes to the immunorecessive nature of epitope V within SV40 Tag. Increasing the delivery of epitope V peptide to the major histocompatibility complex class I presentation pathway by ER targeting dramatically enhanced the immunogenicity of epitope V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445050      PMCID: PMC124628     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen.

Authors:  L M Mylin; A M Deckhut; R H Bonneau; T D Kierstead; M J Tevethia; D T Simmons; S S Tevethi
Journal:  Virology       Date:  1995-04-01       Impact factor: 3.616

2.  Non-producer human cells induced by murine sarcoma virus.

Authors:  J S Rhim; H Y Cho; R J Huebner
Journal:  Int J Cancer       Date:  1975-01-15       Impact factor: 7.396

3.  Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules.

Authors:  G Niedermann; S Butz; H G Ihlenfeldt; R Grimm; M Lucchiari; H Hoschützky; G Jung; B Maier; K Eichmann
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

4.  A simple qualitative spot complementation test for temperature-sensitive mutants of SV40.

Authors:  M J Tevethia; L W Ripper; S S Tevethia
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

5.  SV40 transplantation antigen: relationship to SV40-specific proteins.

Authors:  S S Tevethia; R S Greenfield; D C Flyer; M J Tevethia
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1980

6.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors.

Authors:  R L Brinster; H Y Chen; A Messing; T van Dyke; A J Levine; R D Palmiter
Journal:  Cell       Date:  1984-06       Impact factor: 41.582

8.  Biology of simian virus 40 (SV40) transplantation antigen (TrAg) II. Isolation and characterization of additional temperature-sensitive mutants of SV40.

Authors:  M J Tevethia; L W Ripper
Journal:  Virology       Date:  1977-09       Impact factor: 3.616

9.  Demonstration of multiple antigenic sites of the SV40 transplantation rejection antigen by using cytotoxic T lymphocyte clones.

Authors:  A E Campbell; F L Foley; S S Tevethia
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

10.  Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum.

Authors:  T Elliott; A Willis; V Cerundolo; A Townsend
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  23 in total

1.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

Review 2.  Generation of MHC class I ligands in the secretory and vesicular pathways.

Authors:  Margarita Del Val; Salvador Iborra; Manuel Ramos; Silvia Lázaro
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

3.  CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion.

Authors:  Jarad J Wilson; Christopher D Pack; Eugene Lin; Elizabeth L Frost; Joshua A Albrecht; Annette Hadley; Amelia R Hofstetter; Satvir S Tevethia; Todd D Schell; Aron E Lukacher
Journal:  J Immunol       Date:  2012-03-23       Impact factor: 5.422

Review 4.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

5.  Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Authors:  Danilo R Casimiro; Aimin Tang; Helen C Perry; Romnie S Long; Minchun Chen; Gwendolyn J Heidecker; Mary-Ellen Davies; Daniel C Freed; Natasha V Persaud; Sheri Dubey; Jeffrey G Smith; Diane Havlir; Douglas Richman; Michael A Chastain; Adam J Simon; Tong-Ming Fu; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Authors:  T D Schell; L M Mylin; I Georgoff; A K Teresky; A J Levine; S S Tevethia
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus.

Authors:  T M Fu; D C Freed; W L Trigona; L Guan; L Zhu; R Long; N V Persaud; K Manson; S Dubey; J W Shiver
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Authors:  Byram W Bridle; Jeanette E Boudreau; Brian D Lichty; Jérôme Brunellière; Kyle Stephenson; Sandeep Koshy; Jonathan L Bramson; Yonghong Wan
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

9.  Sympathetic nervous system control of anti-influenza CD8+ T cell responses.

Authors:  Kristie M Grebe; Heather D Hickman; Kari R Irvine; Kazuyo Takeda; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-13       Impact factor: 11.205

10.  An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants.

Authors:  Hephzibah Rani S Tagaram; Alan M Watson; Francois A Lemonnier; Kevin Staveley-O'Carroll; Satvir S Tevethia; Todd D Schell
Journal:  Virology       Date:  2008-04-10       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.